Barely Significant
← all excerpts

<i>CEBPA</i>-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features.

Haematologica · 2017 · PMC5394975 · PMID 28250006

Europe PMCDOI
1
hedged sentence
0.0549
closest p · 1.1× alpha
0.0549
boldest claim

The sentences

showed a trendP =0.0549so close (0.05 < p ≤ 0.1)
In accordance with previous studies, 5 – 7 CEBPA -dm patients, compared to CEBPA -wt patients, showed a trend toward a higher complete remission rate after the first cycle of treatment (87.5% versus 61.0%, respectively; P =0.0549), longer overall survival (median not reached versus 22.3 months, respectively; P =0.00626; Figure 1A ) and longer disease-free survival (median not reached versus 26.8 months, respectively; P =0.0667; Figure 1B ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.